Cite
Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries.
MLA
Rossignol, Patrick, et al. “Time to Retrieve the Best Benefits from Renin Angiotensin Aldosterone System (RAAS) Inhibition in Heart Failure Patients with Reduced Ejection Fraction: Lessons from Randomized Controlled Trials and Registries.” International Journal of Cardiology, vol. 177, no. 3, Dec. 2014, pp. 731–33. EBSCOhost, https://doi.org/10.1016/j.ijcard.2014.11.004.
APA
Rossignol, P., Zannad, F., & Pitt, B. (2014). Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 177(3), 731–733. https://doi.org/10.1016/j.ijcard.2014.11.004
Chicago
Rossignol, Patrick, Faiez Zannad, and Bertram Pitt. 2014. “Time to Retrieve the Best Benefits from Renin Angiotensin Aldosterone System (RAAS) Inhibition in Heart Failure Patients with Reduced Ejection Fraction: Lessons from Randomized Controlled Trials and Registries.” International Journal of Cardiology 177 (3): 731–33. doi:10.1016/j.ijcard.2014.11.004.